Plasma Fractionation Market Growth, Size, Trends Analysis - By Product, By Method, By Application, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Plasma Fractionation Market Introduction and Overview

According to SPER market research, 'Plasma Fractionation Market Growth, Size, Trends Analysis - By Product, By Method, By Application, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Plasma Fractionation Market is predicted to reach 82.93 billion by 2034 with a CAGR of 8.73%.

Plasma fractionation is a manufacturing technique that separates plasma proteins for use in various therapies. Human plasma fractionation provides the foundation for producing a number of life-saving protein medicines, including coagulation factors, albumin, immunoglobulins, protease inhibitors, and more. These plasma-derived pharmaceutical preparations are commonly used in clinical settings to replace intravenous protein therapy in the treatment of immunological, hemostatic, metabolic, and other life-threatening illnesses.

The emergence of recombinant therapies as an alternative to plasma-derived medicines restrains market growth. The recombinant product performance of plasma-derived products is achieved by producing similar proteins in genetically modified cells. It is safer than plasma-derived products because it prevents the transfer of bloodborne diseases. The development of recombinant therapeutics as an alternative to plasma-derived medicines has slowed growth.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Product, By Method, By Application, By End-User.

Regions covere

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Grifols S.A, CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, LFB S.A, Biotest AG, Sanquin, Bio Products Laboratory Ltd, Intas Pharmaceuticals Ltd.

Plasma Fractionation Market Segmentation:

By Product: Based on the Product, Global Plasma Fractionation Market is segmented as; Albumin, Immunoglobulins, Coagulation Factors, Protease inhibitors, Others.

By Method: Based on the Method, Global Plasma Fractionation Market is segmented as; Centrifugation, Depth Filtration, Chromatography, Others.

By Application: Based on the Application, Global Plasma Fractionation Market is segmented as; Neurology, Hematology, Oncology, Immunology, Pulmonology, Others.

By End User: Based on the End Use, Global Plasma Fractionation Market is segmented as; Hospitals & Clinics, Clinical Research, Others.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA2523

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Plasma Fractionation Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Plasma Fractionation Market

7. Global Plasma Fractionation Market, By Product (USD Million) 2021-2034

7.1. Albumin
7.2. Immunoglobulins
- 7.2.1. Intravenous immunoglobulins
- 7.2.2. Subcutaneous immunoglobulins
- 7.2.3. Other immunoglobulins
7.3. Coagulation Factors
- 7.3.1. Factor VIII
- 7.3.2. Factor IX
- 7.3.3. VON WILLEBRAND factor
- 7.3.4. Prothrombin complex concentrates
- 7.3.5. Fibrinogen concentrates
- 7.3.6. Others
7.4. Protease inhibitors
7.5. Others

8. Global Plasma Fractionation Market, By Method (USD Million) 2021-2034

8.1. Centrifugation
8.2. Depth Filtration
8.3. Chromatography
8.4. Others

9. Global Plasma Fractionation Market, By Application (USD Million) 2021-2034

9.1. Neurology
9.2. Hematology
9.3. Oncology
9.4. Immunology
9.5. Pulmonology
9.6. Others

10. Global Plasma Fractionation Market, By End User (USD Million) 2021-2034

10.1. Hospitals & Clinics
10.2. Clinical Research
10.3. Others

11. Global Plasma Fractionation Market, (USD Million) 2021-2034

11.1. Global Plasma Fractionation Market Size and Market Share

12. Global Plasma Fractionation Market, By Region, (USD Million) 2021-2034

12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America

13. Company Profile

13.1. Grifols S.A
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. CSL Limited
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Takeda Pharmaceutical Company Limited
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. Octapharma AG
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. Kedrion S.p.A
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. LFB S.A
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. Biotest AG
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Sanquin
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. Bio Products Laboratory Ltd
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Intas Pharmaceuticals Ltd
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Others